NewTimeSpace News: DAIDO GROUP (00544.HK) plans to issue in total 10 million shares.
NewTimeSpace (newtimespace.com) News, July 30, 2026, BUD APAC(01876.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at USD 3.17 billion, increased by 1.12% YoY
NewTimeSpace (newtimespace.com) News, July 29, 2026, SG GROUP HLDGS(01657.HK) released its Annual Report for the period ended April 30, 2026, Total Revenue stood at HKD 166.25 million, increased by 8.12% YoY
NewTimeSpace News: PINESTONE (00804.HK) plans to issue up to 12.18 million shares by placement, with estimated net proceeds of HKD 60.4 million.
NewTimeSpace (newtimespace.com) News, July 29, 2026, PCPD(00432.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at HKD 593 million, decreased by 6.76% YoY
NewTimeSpace (newtimespace.com) News, July 29, 2026, KIDDIELAND(03830.HK) released its Annual Report for the period ended April 30, 2026, Total Revenue stood at HKD 200.59 million, increased by 1.9% YoY
NewTimeSpace (newtimespace.com) News, July 29, 2026, NEW ORIENTAL-S(09901.HK) released its Annual Report for the period ended May 31, 2026, Total Revenue stood at USD 5.66 billion, increased by 15.53% YoY
NewTimeSpace News: MicroPort NeuroScienti c Corporation announced on 30 July that the Artemis Dream® Self-expanding Intracranial Sirolimus-eluting Stent System developed by its subsidiary has passed the application for special review of innovative medical devices issued by the National Medical Products Administration (NMPA) and entered the special review procedure (fast track).
NewTimeSpace News: IMAGI INTERNATIONAL announced on 29 July that Mr. Wang Haomian has been appointed as Executive Director and Group Vice President, with effect from 10 August 2026.
NewTimeSpace News: Jiangsu Hengrui Pharmaceuticals announced on 29 July that its subsidiary Fujian Shengdi has received the Clinical Trial Approval Notice for HRS5580 for Injection issued by the NMPA, authorising the launch of Phase II clinical trials for the prevention of postoperative nausea and vomiting.
NewTimeSpace News: COSCO SHIPPING Development announced on 29 July that its Board of Directors has approved the proposal to apply for registration and issuance of corporate bonds. The Company intends to issue corporate bonds with an aggregate principal amount not exceeding RMB 6 billion to professional investors. The raised funds will be used for repaying interest-bearing debts, supplementing working capital, as well as project construction and operation.
NewTimeSpace News: Dynasty Digital Holdings announced on 29 July that several preconditions relating to the second tranche subscription shares have not been satisfied, so the second tranche settlement will not proceed, and all obligations of each contracting party under the second tranche shall terminate accordingly.
NewTimeSpace News: Hengrui Pharmaceuticals announced in an announcement dated 29 July that Insulin Sudelidec Injection, a self-developed Category 1 therapeutic biological product of the Company, has obtained marketing approval from the National Medical Products Administration (NMPA) for the treatment of type 2 diabetes in adults.
NewTimeSpace News: Peking University Resources announced on 29 July that after re-evaluating its business development strategy and taking relevant uncertainties and market risks into consideration, the Company resolved not to proceed with the establishment of the joint venture, and has mutually agreed with its counterparty to terminate the joint venture agreement.
NewTimeSpace News: DAIDO GROUP announced on 30 July that the Company has entered into a subscription agreement with the subscriber. It proposes to allot and issue 10 million new shares at HK$1 per share, raising gross and net proceeds of approximately HK$10 million, which will be used for the Group’s general working capital.
NewTimeSpace News: China Resources Pharmaceutical announced on 30 July that CR Shuanghe, its non-wholly-owned subsidiary, intends to acquire approximately 23.50% equity interest in Lier Chemical at a price of RMB 30.07 per share, with an aggregate consideration of roughly RMB 5.656 billion.
